Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Expansion of CD4 dim CD8 + T cells characterizes macrophage activation syndrome and other secondary HLH

Arianna De Matteis, Manuela Colucci, Marianna N. Rossi, Ivan Caiello, Pietro Merli, Nicola Tumino, Valentina Bertaina, Manuela Pardeo, Claudia Bracaglia, Franco Locatelli, Fabrizio De Benedetti, Giusi Prencipe

Blood (2022) 140 (3): 262–273.

https://doi.org/10.1182/blood.2021013549

Published: 2022

Includes: Supplemental data

Journal Articles

Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases

Alexei A Grom, Jeanette Bachir, Veronica Asnaghi, Fabrizio De Benedetti

Blood (2021) 138 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2021-146770

Published: 2021

Journal Articles

Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Fabrizio De Benedetti, Alexei A Grom, Paul Brogan, Claudia Bracaglia, Manuela Pardeo, Giulia Marucci, Despina Eleftheriou, Charalampia Papadopoulou, Pierre Quartier, Jordi Antón, Rikke Frederiksen, Veronica Asnaghi, Maria Ballabio, Cristina de Min

Blood (2021) 138 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2021-147596

Published: 2021

Journal Articles

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Franco Locatelli, MD PhD, Michael B. Jordan, MD, Carl Allen, Simone Cesaro, MD, Carmelo Rizzari, Anupama Rao, Barbara Degar, MD, Tim Garrington, MD, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena Diaz, Michael Henry, MD, Fabrizio De Benedetti, MD, Alexei Grom, Anna Stoltenberg, Mårten Vågerö, Cristina de Min

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-140692

Published: 2020

Journal Articles

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-140766

Published: 2020

Journal Articles

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Franco Locatelli, Michael B. Jordan, MD, Carl E. Allen, MDPhD, Simone Cesaro, MD, Carmelo Rizzari, MD, Anupama Rao, MD, Barbara Degar, MD, Timothy Garrington, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena, MD, Alexei A. Grom, MD, Fabrizio De Benedetti, MD, Walter Giovanni Ferlin, PhD, Maria Ballabio, MD, Cristina De Min, MD

Blood (2018) 132 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood-2018-120810

Published: 2018

Journal Articles

A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH

Michael Jordan, MD, Franco Locatelli Prof, MD, PhD, Carl Allen, MD, PhD, Fabrizio De Benedetti, MD, PhD, Alexei A. Grom, Maria Ballabio, MD, Walter Giovanni Ferlin, PhD, NI-0501-04 Study Group, Cristina De Min, MD

Blood (2015) 126 (23): LBA-3.

https://doi.org/10.1182/blood.V126.23.LBA-3.LBA-3

Published: 2015

NARROW

Expansion of CD4 dim CD8 + T cells characterizes macrophage activation syndrome and other secondary HLH

Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases

Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH

Email alerts

ASH Publications

American Society of Hematology

Expansion of CD4 dim CD8 + T cells characterizes macrophage activation syndrome and other secondary HLH

Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases

Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only